Methylgene, Inc.

Methylgere, Inc.

Jeffrey M Besterman

Jubrail Rahil

Arkadii Vaisburg

Rex Pratt

Daniel Delorme

Oscar Miguel Moradei

Silvana Leit

Sylvie Frechette

Pierre Tessier

Isabelle Paquin

Tammy Mallais

Robert Deziel

David Smil

Robert Déziel

John Mancuso

Simon Roy

Robert A Macleod

Roger Machaalani

Oscar Moradei

William M Siders

Zuomei Li

Tammy C Mallais

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

Inhibitors of histone deacetylase

The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &#x3b2;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &#x3b2;-lactamase inhibitors presently available, and which do not require a &#x3b2;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

Inhibitors of &#x3b2;-lactamase

The invention provides novel &#x3b2;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &#x3b2;-lactamase inhibitors presently available, and which do not possess a &#x3b2;-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as &#x3b2;-lactamase inhibitors and as antibiotics.

Acyl phosphonate inhibitors of &#x3b2;-lactamases

Sulfonamidomethyl phosphonate inhibitors of &#x3b2;-lactamase

The invention relates to the modulation of gene expression. In particular, the invention relates to compositions comprising antisense oligonucleotides which inhibit expression of a gene in operable association with protein effectors of a product of that gene, and methods of using the same. In addition, the invention relates to the modulation of mammalian gene expression regulated by methylation.

Modulation of gene expression by combination therapy

The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &#x3b2;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &#x3b2;-lactamase inhibitors presently available, and which do not require a &#x3b2;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not possess &bgr;-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as &bgr;-lactamase inhibitors and as antibiotics.

&bgr;-lactamase and DD-peptidase inhibitors

The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not possess a &bgr;-lactam pharmacophore. These new inhibitors are fully synthetic, allowing ready access to a wide variety of structurally related analogs. Certain embodiments of these new inhibitors also bind bacterial DD-peptidases, thus potentially acting both as &bgr;-lactamase inhibitors and as antibiotics.

Acyl phosphonate inhibitors of &bgr;-lactamases

The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel &bgr;-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic &bgr;-lactamase inhibitors presently available, and which do not require a &bgr;-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.

Sulfonamidomethyl phosphonate inhibitors of beta-lactamase

Growing community of inventors

Baie d'Urfe, Canada

Jeffrey M Besterman